A major US cancer conference turned its attention to the rapidly advancing field of blood cancer treatment last weekend.
The US National Comprehensive Cancer Network's 2023 Annual Congress took place in person, for the first time since 2019, and focused on blood cancer. It was held in San Francisco, USA, and online, Friday 22nd and Saturday 23rd September.
Among the recent developments in blood cancer treatment were updates to the Network’s own Clinical Practice Guidelines in Oncology, covering CAR T-Cell therapy, BTK Inhibitors, and Bispecific T-Cell Engagers.
Chair of the congress, Dr Andrew Zelenetz of Memorial Sloan Kettering Cancer Center, New York, USA, explained that the programme of events was relevant to the entire haematology and oncology team, “taking into account the latest advances, conversations, and controversies in blood cancer treatment today”.
“Attendees from all over the world can learn about the most up-to-date evidence and expert consensus for improving outcomes for patients with a variety of haematologic malignancies," he added.
“The event also provides opportunities for networking and questions with leading experts in the field.”
Sessions covered topics including toxicities in patients receiving CAR T-cell therapy, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
The programme also looked at bispecific T-cell engagers, an emerging therapy for haematologic cancer, and ways of integrating new World Health Organization and International Consensus Classification systems.
Senior Vice President and Chief Medical Officer of the Network, Dr Wui-Jin Koh, said: “This conference seeks to provide clear, understandable, and actionable updates to help busy care providers analyse, evaluate, and contextualise new clinical data.
“This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape.”
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News.